Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry.

Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG; Members of the Standardization Ad-Hoc Consensus Committee.

Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):513-20. doi: 10.1097/PAI.0b013e31818a9d3a.

PMID:
18931614
[PubMed - indexed for MEDLINE]
2.

Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy.

Diaz LK, Sneige N.

Adv Anat Pathol. 2005 Jan;12(1):10-9. Review.

PMID:
15614160
[PubMed - indexed for MEDLINE]
3.

Current issues in ER and HER2 testing by IHC in breast cancer.

Gown AM.

Mod Pathol. 2008 May;21 Suppl 2:S8-S15. doi: 10.1038/modpathol.2008.34. Review.

PMID:
18437174
[PubMed - indexed for MEDLINE]
Free Article
4.

Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC.

Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R.

J Clin Pathol. 2000 Aug;53(8):634-5.

PMID:
11002770
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Proficiency testing of immunohistochemical biomarker assays in breast cancer.

Wasielewski Rv, Hasselmann S, Rüschoff J, Fisseler-Eckhoff A, Kreipe H.

Virchows Arch. 2008 Dec;453(6):537-43. doi: 10.1007/s00428-008-0688-4. Epub 2008 Oct 29.

PMID:
18958494
[PubMed - indexed for MEDLINE]
6.

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.

PMID:
19173092
[PubMed - indexed for MEDLINE]
7.

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC.

J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3. Review.

PMID:
19755043
[PubMed - indexed for MEDLINE]
8.

The influence of a gene expression profile on breast cancer decisions.

Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW.

J Surg Oncol. 2009 May 1;99(6):319-23. doi: 10.1002/jso.21244.

PMID:
19204954
[PubMed - indexed for MEDLINE]
9.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

PMID:
19380449
[PubMed - indexed for MEDLINE]
Free Article
10.

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19. Review. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

PMID:
20404251
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.1043/1543-2165-134.6.907. Erratum in: Arch Pathol Lab Med. 2010 Aug;134(8):1101.

PMID:
20524868
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

PGRMC1: a new biomarker for the estrogen receptor in breast cancer.

Craven RJ.

Breast Cancer Res. 2008;10(6):113. doi: 10.1186/bcr2191. Epub 2008 Nov 24.

PMID:
19090968
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC; American Society of Clinical Oncology; College of American Pathologists.

Arch Pathol Lab Med. 2010 Jul;134(7):e48-72. doi: 10.1043/1543-2165-134.7.e48. Review.

PMID:
20586616
[PubMed - indexed for MEDLINE]
14.

TGF-beta 1 could be a missing link in the interplay between ER and HER-2 in breast cancer.

Todorović-Raković N.

Med Hypotheses. 2005;65(3):546-51.

PMID:
15913903
[PubMed - indexed for MEDLINE]
15.

Estrogen receptor β.

Younes M, Honma N.

Arch Pathol Lab Med. 2011 Jan;135(1):63-6. doi: 10.1043/2010-0448-RAR.1. Review.

PMID:
21204712
[PubMed - indexed for MEDLINE]
16.

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT.

BMC Cancer. 2009 Jun 16;9:185. doi: 10.1186/1471-2407-9-185.

PMID:
19531212
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program.

Hung T, Wolber R, Garratt J, Kalloger S, Gilks CB.

Pathology. 2010 Dec;42(7):637-42. doi: 10.3109/00313025.2010.520306.

PMID:
21080872
[PubMed - indexed for MEDLINE]
18.

Systematic review on hormone receptor testing in breast cancer.

Nofech-Mozes S, Vella ET, Dhesy-Thind S, Hagerty KL, Mangu PB, Temin S, Hanna WM.

Appl Immunohistochem Mol Morphol. 2012 May;20(3):214-63. doi: 10.1097/PAI.0b013e318234aa12. Review.

PMID:
22505008
[PubMed - indexed for MEDLINE]
19.

Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer.

Mengel M, Hebel K, Kreipe H, von Wasielewski R.

Breast J. 2005 Jan-Feb;11(1):34-40.

PMID:
15647076
[PubMed - indexed for MEDLINE]
20.

Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.

Azizun-Nisa, Bhurgri Y, Raza F, Kayani N.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.

PMID:
19256737
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk